Academic
Oncology
Dr. Edith A. Perez, MD
|
|
Give Review
Edith Perez is an expert in the field of Oncology. She graduated from University of Puerto Rico School of Medicine. She has 32 awards "Top Expert - Breast Cancer", "Claude Jacquillat Award", "Giants of Cancer Care Award", "Clinical Medicine Highly Cited Researcher", "America's Top Doctors", "JU Community Woman of the Year, Womens History Month Committee", "Susan G. Komen - Brinker Award for Scientific Distinction in Clinical Research", "Woman of Vision Award", "America's Top Doctors for Cancer", "75 Most Influential People in Jacksonville Healthcare", "Hispanic Heritage Leadership Award", "Outstanding Course Director", "Alpha Omega Alpha", "Women's Health", "Distinguished Investigator, Executive Board and Research Committee", "Healthcare Heroes Super Scientist", "Honorary Doctorate of Letters", "Serene M. and Frances C. Durling Professor of Medicine", "Outstanding Faculty Member", "Honorary Citizen and Day Proclamation", "North Florida Hispanic of the Year", "Horizon Scientific Cancer Research Award", "Outstanding Faculty Members", "Crusader for Breast Cancer Award", "Celebration of Leadership Award", "Sponsored Research Funding Award", "Fellow", "Sigma Xi, The Scientific Research Society", "NCI Travel Award", "Who's Who in American Women's Biography", "Scholarship" and "Elks Scholarship Award". Edith Perez has written publications. She has 99 publications published with PubMed. The lastest paper is: 'Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized...'
Publications
- Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary Breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
- Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced Breast cancer previously treated with an anthracycline, a taxane, and capec...
- Health-related quality of life in patients with locally advanced or metastatic Breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized...
- Reply to P.G. Gavin et al.
- Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group Cancer clinical trials N02C1 and N03CC (Alliance).
- Reply to E.A. Rakha et al.
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 ...
- Association Studies of Fcγ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831.
- Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.
- EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial.
- Lapatinib with trastuzumab for HER2-positive early Breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their associ...
- Highlights in Breast cancer from the 2014 american society of clinical oncology® annual meeting.
- Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer.
- Immunoscoring Breast cancer: TILs remember what they target.
- Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB...
- Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: American Society...
- Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Gu...
- Central pathology laboratory review of HER2 and ER in early Breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.
- A Phase II Trial of Docetaxel and Carboplatin Administered Every 2 Weeks as Preoperative Therapy for Stage II or III Breast Cancer: NCCTG Study N0338.
- Recommendations for human epidermal growth factor receptor 2 testing in Breast cancer: american society of clinical oncology/college of american pathologists clinical ...
- New developments in metastatic Breast cancer: general discussion.
- Practice-changing data in metastatic Breast cancer.
- Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic Breast cancer: a randomised phase 2 study.
- Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage Breast cancer patients for HER2 status.
- HER2 testing: Current status and future directions.
- Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive Breast cancer receiving chemotherapy with or without trastuzumab: Results...
- Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831.
- Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive Breast cancer in the North Cent...
- A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the Breast.
- Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831.
- TSPYL5 SNPs: Association with Plasma Estradiol Concentrations and Aromatase Expression.
- RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive Breast cancer.
- Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Brea...
- Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27--A Randomized Controlled Phase III Trial.
- Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for Breast cancer (NCCTG N9831, BCIRG 006, and BC...
- Impact of premenopausal status at Breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.
- Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bev...
- How relevant is hormone receptor status in the context of outcome to HER2-positive Breast cancer?
- Analysis of Regional Timelines To Set Up a Global Phase III Clinical Trial in Breast Cancer: The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Experience.
- Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable Breast cancer.
- New treatment paradigms for optimizing survival in advanced and metastatic Breast cancer.
- Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for Breast cancer in women with zero to three pos...
- Next-Generation Targeted Agents in HER2-Positive Metastatic Breast Cancer.
- Race and Hormone Receptor-Positive Breast Cancer Outcomes in a Randomized Chemotherapy Trial.
- Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria.
- Treatment of HER2-positive Breast cancer: current status and future perspectives.
- Trastuzumab emtansine in human epidermal growth factor receptor 2-positive Breast cancer: a review.
- Sequential versus concurrent trastuzumab in adjuvant chemotherapy for Breast cancer.
- Current and emerging targeted therapies for metastatic Breast cancer.
- Final 5-year results of Z-FAST trial: Adjuvant Zoledronic Acid Maintains Bone Mass in Postmenopausal Breast Cancer Patients Receiving Letrozole.
- Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic Breast cancer patients enrolled in North Central Cancer Treatment Group (NCCT...
- Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer.
- Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data From...
- Patient age and preoperative Breast MRI in women with Breast cancer: biopsy and surgical implications.
- A novel bioinformatics pipeline for identification and characterization of fusion transcripts in Breast cancer and normal cell lines.
- RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth ...
- Menstrual history and quality-of-life outcomes in women with node-positive Breast cancer treated with adjuvant therapy on the NSABP B-30 trial.
- Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor ...
- MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of Breast cancer.
- C-MYC alterations and association with patient outcome in early-stage HER2-positive Breast cancer from the north central cancer treatment group N9831 adjuvant trastuzu...
- Breast cancer management: opportunities and barriers to an individualized approach.
- Integrated analysis of gene expression, CpG island methylation, and gene copy number in Breast cancer cells by deep sequencing.
- HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.
- Challenges in applying recent clinical trial data to the care of patients.
- Metastasectomy and surgical resection of the primary tumor in patients with stage IV Breast cancer: time for a second look?
- Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay.
- Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung Cancer: A North C...
- Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Gr...
- Longer therapy, iatrogenic amenorrhea, and survival in early Breast cancer.
- Adjuvant trastuzumab for HER2-positive early Breast cancer.
- Changes to adjuvant systemic therapy in Breast cancer: a decade in review.
- Variation in anastrozole metabolism and pharmacodynamics in women with early Breast cancer.
- In newly diagnosed Breast cancer, screening MRI of the contralateral Breast detects mammographically occult cancer, even in elderly women: the mayo clinic in Florida e...
- Prognosis and outcome of small (<=1 cm), node-negative Breast cancer on the basis of hormonal and HER-2 status.
- Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in Breast cancer.
- Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followe...
- Breast cancer in Latinas: gene expression, differential response to treatments, and differential toxicities in Latinas compared with other population groups.
- Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive Breast cancer.
- Menstrual cycle and surgical treatment of Breast cancer: findings from the NCCTG N9431 study.
- Anthracycline- and/or taxane-resistant Breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
- Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
- Treatment options for Breast cancer resistant to anthracycline and taxane.
- Quality of life after Breast cancer surgery: What have we learned and where should we go next?
- Radiotherapy and adjuvant trastuzumab in operable Breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.
- Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early Breast cancer receiving adjuvant letrozole: Z-FAST stu...
- Comprehensive diagnostic program for medically underserved women with abnormal Breast screening evaluations in an urban population.
- Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response.
- Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary ...
- Phase II trial of sorafenib in patients with metastatic Breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Cl...
- Trastuzumab.
- p120 catenin induces opposing effects on tumor cell growth depending on E-cadherin expression.
- Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.
- Prognostic utility of the 21-gene assay in hormone receptor-positive operable Breast cancer compared with classical clinicopathologic features.
- Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable Breast cancer with 0 to 3 positive axillary n...
- HER2-positive Breast cancer: current treatment strategies.
- Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.
- Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription po...
- Late extended adjuvant treatment with letrozole improves outcome in women with early-stage Breast cancer who complete 5 years of tamoxifen.
Schools
University of Puerto Rico Medical Sciences Campus
Conditions Treated
- Breast Cancer
- Liver Cancer
- Lung Cancer
- Secondary Malignancies
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Top Expert - Breast Cancer
- Claude Jacquillat Award
- Giants of Cancer Care Award
- Clinical Medicine Highly Cited Researcher
- America's Top Doctors
- JU Community Woman of the Year, Womens History Month Committee
- Susan G. Komen - Brinker Award for Scientific Distinction in Clinical Research
- Woman of Vision Award
- America's Top Doctors for Cancer
- 75 Most Influential People in Jacksonville Healthcare
- Hispanic Heritage Leadership Award
- Outstanding Course Director
- Alpha Omega Alpha
- Women's Health
- Distinguished Investigator, Executive Board and Research Committee
- Healthcare Heroes Super Scientist
- Honorary Doctorate of Letters
- Serene M. and Frances C. Durling Professor of Medicine
- Outstanding Faculty Member
- Honorary Citizen and Day Proclamation
- North Florida Hispanic of the Year
- Horizon Scientific Cancer Research Award
- Outstanding Faculty Members
- Crusader for Breast Cancer Award
- Celebration of Leadership Award
- Sponsored Research Funding Award
- Fellow
- Sigma Xi, The Scientific Research Society
- NCI Travel Award
- Who's Who in American Women's Biography
- Scholarship
- Elks Scholarship Award
Education
-
Loma Linda University -
University of Puerto Rico School of Medicine
Hospital
-
Mayo Clinic - Jacksonville, Florida
Helpful Reviews
Similar Doctors
|
|
Dr. Safeer A. Ashraf, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kurt A. Jaeckle, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Zhen Hou, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Sahana R. Kalmadi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William C. Rupp, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dimitrios P. Agaliotis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Winston W. Tan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mohammad Asif Khan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Melanie J. Kubik, MD
This Doctor is OpenDoctor Recommended.
|